Navigation Links
Study Uncovers Key Success Factors and Common Failure Points for Launching New Metabolic Products in Today's Competitive Healthcare Market
Date:9/2/2011

CHAPEL HILL, N.C.,  Sept. 2, 2011 /PRNewswire/ -- One of the more difficult aspects of planning a new metabolic product launch is balancing the different resource and investment allocations that are needed to prepare the marketplace for a new product.  In particular, organizations wrestle with allocating the appropriate resources for informing key stakeholders as well as other critical launch activities that are carried out across different functional areas.

How does a pharma or biotech company successfully launch a new product into a crowded, competitive marketplace?

Among the several other strategies is this: Many companies seek to gain greater commercial traction in early market entry simply by investing at and above market-leader levels. 

In fact, according to "Success Factors and Failure Points in Metabolic Product Launches," a recent study from Best Practices, LLC, more than half of companies (64%) from a benchmark class of 38 top companies favor spending between 101% - 150% of the market leader's investment level during product launch.

In addition to launch spending, recent market entries have illustrated that there are a critical core set of factors for metabolic products as well as other therapeutic areas: differentiation, defining a target patient population, thought leader engagement, education of key stakeholders, demonstrating value, and use of new technologies.

"Success Factors and Failure Points in Metabolic Product Launches" explores each aspect of this framework for launch success and provides a metabolic segment as well as a data segment representing other therapeutic areas combined.  This comprehensive launch study delivers qualitative and quantitative data on differentiation, pricing, physician and thought leader education, payer and formulary access, launch readiness, resource allocation and much more.

To download a complimentary study excerpt, go to: http://www3.best-in-class.com/rr1112.htm.

Best Practices, LLC used both field surveys and interviews to complete this study. In all, 44 managers and executives at 38 leading bio-pharma companies participated in the survey.  In-depth interviews were conducted with leaders from six organizations who have decades of experience with pharma launches.

Key topics examined in this study include:

  • Winning on Differentiated Product Positioning
  • Winning a Physician's Initial Trial of a New Product
  • Articulating Benefits that Shape Positive Market Perception
  • New Product Pricing Strategy
  • Thought Leader Engagement
  • Physician & Payer Education
  • Preparing Market Constituents
  • Winning Hospital Formulary Access
  • Resource Allocation & Timing

For more information, contact Cameron Tew, Executive Director of Research and Publishing at Best Practices, LLC at (919) 767-9246 or ctew@best-in-class.com.

BEST PRACTICES, LLC conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for more than 17 years; our clients include 48 of the top 50 pharmaceutical companies.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Explores Utilization Trends for Prostate Cancer Treatments
2. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
3. Kuros Completes Patient Recruitment in its European Clinical Study With KUR-023, its Novel Dural Sealant Product Candidate
4. New Study Shows Modified Citrus Pectin Activates Powerful Immune Responses
5. Ultragenyx Initiates Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Muscle Wasting Disease
6. Comparative Study Confirms Enox Biopharmas Antimicrobial Superiority to Commercially Available Silver Coated Catheters
7. Allergy Technologies LLC Provides Over $100,000 in a Research Grant to The Ohio State University for the Study of Bed Bugs
8. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
9. BridgePoint Medical Announces US IDE Approval and First Patient Enrollment of Peripheral Chronic Total Occlusion Study
10. Study Shows That Salt Lake City Based Company Has Program That Enhances Brain Activity
11. Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ... present a company overview at the BMO Capital Markets Prescriptions for ... York, NY . A live webcast of the ... the Ionis website.  The replay will be available within 48 hours ... ...
(Date:12/7/2016)... 7, 2016 Today, Stock-Callers.com presents four ... JAZZ ), Anthera Pharmaceuticals Inc. (NASDAQ: ANTH ... AveXis Inc. (NASDAQ: AVXS ). From its peak ... 37% to reach a level equal to what it saw ... approximately 14% for the year, it has still out-performed other ...
(Date:12/7/2016)... According to the latest market ... Study on Multiplex Detection Immunoassay: North America to Dominate ... detection immunoassay market is expected to witness a CAGR of ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... ... They are musicians and librarians, fashion designers and fitness instructors, actors, athletes and ... around the nation. What do they have in common? All have been affected by ... new photographic exhibit debuting Friday, December 9 at Logan International Airport in Boston. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... connectors, is now promoting to the US market its advanced highly customizable contact ... and ODU TURNTAC®. These advanced technologies are ideal for a wide range ...
(Date:12/7/2016)... MI (PRWEB) , ... December 07, 2016 , ... ... and financial consultation services from offices located in South Lyon, Dewitt, Williamston, East ... benefit a basketball coach who needs treatment for a brain tumor. , Jason ...
(Date:12/7/2016)... Folsom, CA (PRWEB) , ... December 07, 2016 ... ... that provides insurance and financial consultation services to residents in the Sacramento/Folsom region, ... Choice Another Chance treatment facility. , The Another Choice Another Chance treatment center ...
Breaking Medicine News(10 mins):